One day after Boehringer IngelheimĀ presented so-so data from a successful trial of its highly touted idiopathic pulmonary fibrosis (IPF) candidate...
One day after Boehringer IngelheimĀ presented so-so data from a successful trial of its highly touted idiopathic pulmonary fibrosis (IPF) candidate...